COVID-19 Vaccine Safety Now: Soft Rollout, Not Pause, After Reports Of Guillain-Barré Syndrome
Executive Summary
Unlike its response to incidents of blood clots with J&J’s vaccine, the US FDA is not calling for a pause in its administration following reports of about 100 cases of Guillain-Barré syndrome. CDC advisory panel is to discuss the issue at an upcoming meeting.
You may also be interested in...
Janssen COVID-19 Vaccine Adds Another Thrombotic Warning
US FDA adds a warning about immune thrombocytopenia, joining the risk of Thrombosis with Thrombocytopenia Syndrome.
Coronavirus Update: India Grants Emergency Approval To J&J Vaccine
India has issued an emergency authorization to J&J's single-dose COVID-19 vaccine, while a South Korean report calls for improved vaccine handling standards amid lapses and losses.
The Indemnity Calculus For Covid-19 Vaccines, India’s Path Ahead
Legal experts discuss the intricacies around pharma’s demand for indemnity, a key sticking point for supplies of COVID-19 vaccines from Pfizer and Moderna, and the path forward for countries like India.